The use of eldecalcitol alone or along with a bone resorption inhibitor offers numerous advantages in people with osteoporosis having distal radius fractures, as concluded from a study issued in Journal of Orthopaedic Science.

Distal radius fractures are a frequent occurrence in osteoporotic individuals with many of these fractures resulting from falls, associated with a person's limb muscle mass, strength, and exercise capability.

Given the limited evidence linked with the use of bone resorption inhibitor in osteoporosis, Kazushige Maeda and researchers determined the effects of eldecalcitol alone or combined with a bone resorption inhibitor in postmenopausal women with distal radius fractures which may serve as recognition of preventive effects against fractures in future.

The results of physical tests concerning bone, limb and skeletal muscle mass were assessed before and after a year of therapy in a total of 99 women with distal radius fractures. A questionnaire was used to examine the occurrences of fall recurrence and refracture.

Overall, 85 patients accomplished follow-up assessments for over a year. Significant improvements were observed in bone mass and bone mineral density in lower back region and total proximal femur than prior to the therapy. Also, skeletal muscle mass index, grip strength on and quadriceps muscle strength, fitness tests (walking speed and two-step test) results also improved. Fall recurrence and refracture was observed in 19 and 4 patients.